Abstract
Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using evidence from melanoma research, both published and in process.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Antineoplastic Agents, Immunological / administration & dosage*
-
Duration of Therapy*
-
Humans
-
Ipilimumab / administration & dosage
-
Melanoma / drug therapy*
-
Melanoma / secondary
-
Nivolumab / administration & dosage*
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Skin Neoplasms / pathology
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
Ipilimumab
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
Nivolumab
-
pembrolizumab